Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Data on cancer vaccines discussed by researchers at Children's Hospital, Department of Hematology-Oncology
September 23rd, 2008
A report, 'CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans,' is newly published data in Clinical Cancer Research. According to a study from the United States, "CpG oligodeoxynucleotides (CpG-ODN) are being investigated as cancer vaccine adjuvants because they mature plasmacytoid dendritic cells (PDC) into potent antigen-presenting cells. CpG-ODN also induce PDC to secrete chemokines that alter lymphocyte migration." "Whether CpG-ODN TLR signals enhance antigen-specific immunity and/or trafficking in humans is unknown. We conducted a phase I study of CpG-ODN (1018 ISS) given as a vaccine adjuvant with granulocyte-macrophage...
Source: Cancer Weekly (2008-09-23)
|
